Congenital alveolar dysplasia

Summary

Congenital alveolar dysplasia (MONDO:0100077) is a disease. A subtype of congenital pulmonary veins anomaly — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	congenital alveolar dysplasia
Mondo ID	MONDO:0100077
UMLS	C0035220
MedGen	20539
GARD	0026035
Is cancer (heuristic)	no

Also known as: CAD

Disease family

This is a subtype of congenital pulmonary veins anomaly. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › congenital heart disease › congenital pulmonary veins anomaly › congenital alveolar dysplasia

Related subtypes (3): alveolar capillary dysplasia with misalignment of pulmonary veins, congenital pulmonary venous return anomaly, alveolar capillary dysplasia without misalignment of pulmonary veins

Subtypes (2): congenital alveolar dysplasia due to FGF10, congenital alveolar dysplasia due to TBX4

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.